Abivax SA saw a notable increase in its stock price following a series of strategic developments.
Abivax SA American Depositary Shares (NASDAQ:ABVX) went up yesterday by 6.36%, closing at CA$96.85. This surge is due to the company’s recent business updates and financial results, which showed a strong cash position and new leadership appointments.
Advertisement
Abivax SA American Depositary Shares
ABVX.US
ABVX.US
Abivax SA American Depositary Shares
WealthAwesomeMarket cap
$8.45B
52W high
$148.83
52W low
$69.81
1W change
-6.38%
Beta
-0.25
Analyst Price Targets
Based on 7 analysts covering ABVX · as of Sep 23, 2026
Wall Street analysts forecast ABVX stock price to rise 69.3% over the next 12 months.
Consensus
Buy4.43 / 5.00
Avg. Target
C$164.00
+69.3% Upside
Previously C$165.00 on Sep 17, 2026
Current Price
C$96.85
Last close
Analyst Breakdown (7 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ABVX's historical volatility
30-Day Vol
47.6%
Annualized
90-Day Vol
78.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$81.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$91.25 | C$77.43 – C$107.55 |
| 60 trading days | C$85.98 | C$68.15 – C$108.47 |
| 90 trading days | C$81.01 | C$60.95 – C$107.68 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are encouraged by Abivax's solid financial standing and strategic initiatives, which may set the company up for future growth.
6.36%
Abivax's stock price increase reflects growing investor confidence following significant corporate developments.
Bull case
With a strong cash runway extending into Q4 2029 and positive interactions with the FDA regarding its lead drug candidate, Abivax is well-positioned to advance its clinical programs and increase shareholder value.
Bear case
Despite the positive momentum, investors should stay cautious as the biotechnology sector is inherently volatile and relies heavily on regulatory approvals and clinical trial outcomes.
Strong Financial Position
Advertisement
Abivax's recent financial results revealed that the company had €402.4 million in cash and equivalents as of June 30, 2026. This, along with €767.1 million raised from a public offering, gives the company a strong cash runway and positions it well for future investments in its clinical programs.
Leadership Changes and Strategic Direction
The appointment of Chris Rabbat as Chief Medical Officer and Tim Kelly as Chief Technical Officer shows Abivax's commitment to improving its operational capabilities. These leadership changes are expected to drive the company's strategic initiatives in developing therapeutics for chronic inflammatory diseases.
Positive Regulatory Engagement
Abivax's positive pre-NDA interaction with the FDA regarding its lead drug candidate, obefazimod, is a significant milestone. This engagement is crucial for the company's path toward potential regulatory approval, which could further boost investor confidence and stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
